Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
This NIH R21 funds development of next-generation brain stimulation devices for mental health disorders, either wholly new stimulation approaches or significant upgrades to FDA-cleared devices. App…
- Deadline
- Jan 7, 2028
- Posted
- Nov 21, 2024
- Award amount
- Amount not specified
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Jan 7, 2028 so you have time to apply.
In plain English
This NIH R21 funds development of next-generation brain stimulation devices for mental health disorders, either wholly new stimulation approaches or significant upgrades to FDA-cleared devices. Applicants should be multidisciplinary research teams spanning neuroscience, engineering, and regulatory expertise at eligible research institutions. No award amount is specified, and incremental software updates alone don't qualify.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates)are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with a variety of expertise including systems neuroscience, engineering, clinical, and regulatory affairs.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due in 2 days
Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
National Institutes of Health · Up to $50K · Due in 2 days
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due in 2 days
Community Engagement Evaluation and Data Coordination (CEED) Hub to Advance Data and Practice Transformation for Optimizing Oral Health for All (U01, Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 2 days
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
National Institutes of Health · Amount varies · Due in 24 days
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
National Institutes of Health · Up to $1.1M · Due in 27 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.